Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.07Last Year’s EPS
0.75Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong 2025 execution: double-digit growth in royalty and portfolio receipts, attractive returns (ROIC 15.8%, ROIE 22.8%), record synthetic royalty activity, achievement of capital deployment targets ahead of schedule, significant cash generation ($2.7B portfolio cash flow) and meaningful shareholder returns (repurchases and a 7% dividend increase). Offsetting factors include moderated 2026 top-line guidance (royalty growth 3%–8%), a sizable expected drop in milestone receipts (~$68M), higher interest expense in 2026, and execution/timing risk around several pivotal clinical readouts and an ongoing arbitration. Overall, the positives around growth, returns, liquidity, synthetic royalty momentum, and cost savings from internalization outweigh the near-term headwinds and event risks.Company Guidance
Strong Top-Line Growth
Royalty receipts grew 13% for the full year and 17% in Q4; portfolio receipts (including milestones) grew 16% for the year and 18% in Q4, outperforming initial guidance and prompting three guidance raises during 2025.
Attractive Returns Metrics
Return on invested capital was 15.8% and return on invested equity was 22.8% for 2025, supported by a sale of MorphoSys development bonds that generated ~$511M proceeds and ~25% IRR on that investment.
Material Capital Deployment and Shareholder Returns
Announced transaction value totaled $4.7B in 2025; deployed capital was $2.6B for the year (including $887M in Q4). Returned $1.7B to shareholders via $1.2B in share repurchases (37M shares) and >$500M in dividends; weighted average share count declined ~5%.
Internalization Delivered Cost Savings
Manager internalization completed in May 2025 drove operating/professional costs down to 6.7% of portfolio receipts in Q4 (8.9% for the year). Company expects 2026 operating/professional costs of 5%–6.5% of portfolio receipts and $100M of run-rate savings in 2026.
Synthetic Royalties Momentum
2025 was the strongest year ever for synthetic royalty transactions: four synthetic deals totaling >$2B and the market value for synthetics jumped ~50% year-over-year to ~$4.7B; synthetic announced value exceeded existing royalties in committed capital for the first time.
Robust Portfolio and Pipeline Potential
Portfolio includes 20 development-stage therapies with combined non-risk-adjusted peak sales >$43B, which the company estimates could translate into >$2.1B in peak annual royalties; multiple pivotal readouts expected over the next 24 months.
Strong Cash Generation and Liquidity
Portfolio cash flow (adjusted EBITDA less net interest) was $815M in Q4 and $2.7B for the year; cash and equivalents totaled $619M, and the company has access to >$3.5B of financial capacity (including $9.2B investment-grade debt and an undrawn $1.8B revolver).
Dividend Increase and Capital Return Discipline
Dividend was increased by 7% for 2026 consistent with mid-single-digit growth target; management emphasized a dynamic capital allocation framework balancing buybacks, dividends, and royalty investments.
RPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 11, 2026 | $43.98 | $44.02 | +0.09% |
Nov 05, 2025 | $37.43 | $39.99 | +6.82% |
Aug 06, 2025 | $37.28 | $36.50 | -2.08% |
May 08, 2025 | $31.99 | $32.33 | +1.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Royalty Pharma PLC (RPRX) report earnings?
Royalty Pharma PLC (RPRX) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Royalty Pharma PLC (RPRX) earnings time?
Royalty Pharma PLC (RPRX) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RPRX EPS forecast?
RPRX EPS forecast for the fiscal quarter 2026 (Q1) is 1.07.